By Stephen Nakrosis
Shares of Telomir Pharmaceuticals were trading higher in Wednesday's after-hours market, following the company's report on its Telmor-1 anti-aging and longevity treatment.
After the bell, the company's shares were trading 4.7% higher, at $4.40. The stock finished the day's regular session with a 5.4% loss, closing at $4.20.
Telomir said a study demonstrated significant age-reversal effects in aging model organisms treated with Telomir-1. Effects included an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decline, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 20, 2024 18:44 ET (23:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。